Elicio Therapeutics, a biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. This inclusion marks a milestone reflecting growing recognition of Elicio's advancements, particularly with its lead product ELI-002 7P targeting KRAS mutations in cancers like pancreatic and colorectal cancer. The company plans to advance clinical trials, including a Phase 1 study in metastatic pancreatic cancer, aiming to improve treatment strategies and expand indications. Being part of these indexes increases Elicio's visibility among institutional investors and supports its commitment to delivering value to patients and shareholders.
Best Buy reported a strong fiscal Q2 2027 with revenue up 3.6% to $9.78 billion and comparable sales rising 4.1%, surpassing expectations. Adjusted diluted EPS increased 15% to $1.47, helped partly by $34 million in tariff refunds. Following these re...
BP, a major global energy company, is actively managing its portfolio by potentially selling oil and gas assets in Egypt to Energean and investing in new projects like a Halliburton contract in Brazil's offshore field. This strategic move aims to enh...
Cardano's constitutional committee must ratify a governance action by September 6, 2026, to renew four of its seven seats. If not ratified by then, the committee falls below its minimum size of five members, causing a governance standstill where no m...
Bitcoin mining currently consumes 30% of Paraguay's energy, mainly from hydroelectric sources, raising concerns about a potential energy crisis by 2029 if demand continues to grow. Analysts warn that stagnant power generation and a $15 billion invest...
Pernod Ricard reported Q4 2026 earnings per share of $0.42 and revenue of $4.90 billion, both surpassing analyst expectations. However, the company faces significant organic sales declines of 14% in the US and 19% in China due to weak consumer demand...
